coaprovel
sanofi winthrop industrie - irbesartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. this fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.
aprovel
sanofi winthrop industrie - irbesartan - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.
co-aprovel 300 mg, 12.5 mg
شركة ألفه للأدوية - ulfa pharma co. - irbesartan 300 mg, hydrochlorothiazide 12.5 mg - 300 mg, 12.5 mg
coaprovel film-coated tablet 30025mg
sanofi-aventis singapore pte. ltd. - hydrochlorothiazide; irbesartan - tablet, film coated - 25.00mg - hydrochlorothiazide 25.00mg; irbesartan 300.00mg
coaprovel film-coated tablet 15012.5 mg
sanofi-aventis singapore pte. ltd. - hydrochlorothiazide; irbesartan - tablet, film coated - 12.50 mg - hydrochlorothiazide 12.50 mg; irbesartan 150.00 mg
coaprovel film-coated tablet 30012.5 mg
sanofi-aventis singapore pte. ltd. - hydrochlorothiazide; irbesartan - tablet, film coated - 12.50 mg - hydrochlorothiazide 12.50 mg; irbesartan 300.00 mg
coaprovel 300mg12.5mg tablets
sanofi - irbesartan; hydrochlorothiazide - tablet - 300mg ; 12.5mg
coaprovel 150mg12.5mg tablets
sanofi - hydrochlorothiazide; irbesartan - tablet - 12.5mg ; 150mg
aprovel 150mg tablets
sanofi - irbesartan - tablet - 150mg
aprovel 300mg tablets
sanofi - irbesartan - tablet - 300mg